Medication status of new bisphosphonate users at the end of 12Â months follow up | ||||
---|---|---|---|---|
 | Continued original bisphosphonate use | Discontinued without switching or restarting | Restarted the same bisphosphonates after a treatment gap | Switched to another anti-osteoporosis medication |
N | 9,510 | 7,827 | 1,819 | 2,296 |
Age, years (SD) | 78 (6.8) | 78 (6.8) | 78 (6.7) | 78 (6.8) |
Median Household Income, $ (SD) | 46,318 (22,808) | 44,415 (22,715) | 45,015 (23,123) | 45,142 (22,540) |
Sex | Â | Â | Â | Â |
Female | 8,562 (90.3) | 6,965 (89.0) | 1,639 (90.1) | 2,104 (91.6) |
Male | 948 (10.0) | 862 (11.0) | 180 (9.9) | 192 (8.4) |
Race/ethnicity | Â | Â | Â | Â |
Black | 455 (4.8) | 455 (5.8) | 125 (6.9) | 94 (4.1) |
White | 8,194 (86.2) | 6,486 (82.9) | 1,456 (80.0)* | 1,920 (83.6) |
Asian | 360 (3.8) | 319 (4.1) | 92 (5.1) | 130 (5.7) |
Hispanic | 285 (3.0) | 382 (4.9) | 95 (5.2) | 107 (4.7) |
Other | 216 (2.3) | 185 (2.4) | 51 (2.8) | 45 (2.0) |
Geographic region | Â | Â | Â | Â |
Northeast | 1,717 (18.1) | 1,340 (17.1) | 355 (19.5) | 382 (16.6) |
Midwest | 2,534 (26.6) | 1,805 (23.1) | 417 (22.9) | 568 (24.7) |
South | 3,540 (37.2) | 3,287 (42.0) | 701 (38.5) | 903 (39.3) |
West | 1,719 (18.1) | 1,395 (17.8) | 346 (19.0) | 443 (19.3) |
Charlson score | Â | Â | Â | Â |
0 | 3,945 (41.5) | 3,007 (38.4) | 712 (39.1) | 937 (40.8) |
1-3 | 3,831 (40.3) | 3,222 (42.2) | 783 (43.0) | 931 (40.5) |
> 3 | 1,734 (18.2) | 1,598 (20.4) | 324 (17.8) | 428 (18.6) |
Hospitalizations | 2,350 (24,7) | 1,961 (25.1) | 448 (24.6) | 623 (27.1)* |
In long-term care | 1,146 (12.1)* | 659 (8.4) | 156 (8.6) | 303 (13.2) |
History of any fractures | 1,051 (11.1) | 704 (9.0) | 162 (8.9) | 272 (11.8) |
History of DXA | 5,641 (59.3)* | 4,154 (53.1) | 883 (48.5) | 1,328 (57.8) |
Dual Eligible | 2,807 (29.5) | 2,624 (33.5) | 650 (35.7) | 779 (33.9) |
Eligible for low income subsidy | 3,011 (31.7) | 2,877 (36.8) | 690 (37.9) | 841 (36.6) |
Entered Medicare part D coverage gap | 1,826 (19.2) | 1,613 (20.6) | 367 (20.2) | 471 (20.5) |
Proton pump inhibitors | 2,430 (25.6) | 2,070 (26.5) | 517 (28.4) | 709 (30.9) |
Doctor visit type | Â | Â | Â | Â |
Internal Medicine visits | 6,220 (65.4) | 5,085 (65.0) | 1,170 (64.3) | 1,564 (68.1) |
Family Practice visits | 4,446 (46.8) | 3,654 (46.7) | 781 (42.9) | 1,107 (48.2) |
Medical Oncology visits | 940 (9.9) | 721 (9.2) | 159 (8.7) | 222 (9.7) |
Rheumatology/Endo visits | 1,706 (17.9) | 1,150 (14.7) | 304 (16.7) | 430 (18.7)* |
Number of Physician Visits | Â | Â | Â | Â |
0-5 | 2,978 (31.3) | 2,305 (29.4) | 571 (31.4) | 579 (25.2) |
6-10 | 2,516 (26.5) | 2,018 (25.8) | 462 (25.4) | 578 (25.2) |
11-15 | 1,665 (17.5) | 1,379 (17.6) | 307 (16.9) | 438 (19.1) |
> 15 | 2,351 (24.7) | 2,125 (27.1) | 479 (26.3) | 701 (30.5) |